9OKF

Cryo-EM structure of human SV2A in the apo state

9OKF の概要

• エントリーDOI: 10.2210/pdb9okf/pdb
• EMDBエントリー: 70562
• 分子名称: Synaptic vesicle glycoprotein 2A (1 entity in total)
• 機能のキーワード: slc transporter, slc22 family, membrane protein, apo state
• 由来する生物種: Homo sapiens
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 67822.16

構造登録者

Pidathala, S.,Dai, Y.,Lee, C.H. (登録日: 2025-05-09, 公開日: 2025-12-10)

主引用文献

Pidathala, S.,Chen, X.,Dai, Y.,Nguyen, L.N.,Gorgulla, C.,Niu, Y.,Liu, F.,Lee, C.H.
Structural pharmacology of SV2A reveals an allosteric modulation mechanism in the major facilitator superfamily.
Nat Commun, 16:10748-10748, 2025

PubMed Abstract: The synaptic vesicle glycoprotein 2A (SV2A), a member of the major facilitator superfamily (MFS), is a key target for antiseizure medications and a biomarker for synaptic density imaging. Despite its clinical importance, the mechanisms underlying SV2A ligand binding and modulation remain poorly understood. Here, we report sub-3 Å resolution cryo-electron microscopy (cryo-EM) structures of human SV2A in its apo form and in complex with FDA-approved antiseizure medication levetiracetam; PET imaging tracer UCB-J; experimental antiseizure drug padsevonil; and allosteric modulator UCB1244283. We find that levetiracetam and UCB-J induce vestibule occlusion, a hallmark conformational transition of MFS transporters that had not been observed in previous SV2A structures. UCB1244283 binds to an allosteric site and enhances orthosteric ligand engagement by stabilizing the occluded state and slowing ligand dissociation. Notably, padsevonil occupies both orthosteric and allosteric sites, functionally precluding modulation. These findings uncover an allosteric mechanism of regulation and provide a structural framework for the development of modulators targeting SV2A and related MFS transporters.

PubMed: 41315229
DOI: 10.1038/s41467-025-65781-1

実験手法

ELECTRON MICROSCOPY (2.8 Å)